The Nasdaq Biotechnology Index will include Guilford biotech firm Quantum-Si starting on Dec. 20, the company announced Wednesday.
Nasdaq announced the inclusion of Quantum-Si on Dec. 10 as part of its annual reconstitution of its bioscience index. The Biotechnology Index tracks the performance of a select group of biotechnology or pharmaceutical securities.
Nasdaq indexed companies must meet a set of standards including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria.
Quantum-Si, which focuses on protein-sequencing technology, was founded by Jonathan Rothberg in 2013 and went public in June following a SPAC deal valued at $1.46 billion.
The company’s stock, listed on the Nasdaq under the symbol QSI, debuted at $10.75 a share in June but was trading at only $5.93 as of Wednesday, 40% below its peak.
Quantum-Si acquired Majelac Technologies LLC in November in a deal expected to prevent supply chain woes by bringing chip assembly and packaging capabilities in-house.
Contact Liese Klein at lklein@newhavenbiz.com.
